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OBJECTIVES The aim of this study was to assess the prognostic importance of left ventricular ejection
fraction (LVEF) in stable outpatients with heart failure (HF).
BACKGROUND Although LVEF is an accepted prognostic indicator of prognosis in HF patients, the
relationship of LVEF and mortality across the full spectrum of LVEF is incompletely
understood.
METHODS We examined the association of LVEF and outcomes among 7,788 stable HF patients
enrolled in the Digitalis Investigation Group trial.
RESULTS During mean follow-up of 37 months, mortality was substantial in all LVEF groups (range,
LVEF 15%, 51.7%, LVEF 55%, 23.5%). Among patients with LVEF 45%, mortality
decreased in a near linear fashion across successively higher LVEF groups (LVEF  15%,
51.7%; LVEF 36% to 45%, 25.6%; p  0.0001). This association was present after
multivariable adjustment, although the magnitude of this associated risk was reduced (LVEF
 15%: hazard ratio [HR] 1.77, 95% confidence interval [CI] 1.48 to 2.11; LVEF 16% to
25%: HR 1.44, 95% CI 1.28 to 1.61; LVEF 26% to 35%: HR 1.10, 95% CI 0.98 to 1.28;
LVEF 36% to 45%: referent). In contrast, mortality rates were comparable among patients
with LVEF  45% both before (LVEF 46% to 55%: 23.3%; LVEF  55%: 23.5%; p 
0.25), and after multivariable adjustment (LVEF 46% to 55%: HR 0.92, 95% CI 0.77 to 1.10;
LVEF  55%: HR 0.88, 95% CI 0.71 to 1.09; LVEF 36% to 45%: referent). Patients with
lower LVEF were at increased absolute risk of death due to arrhythmia and worsening HF,
but these were leading causes of death in all LVEF groups.
CONCLUSIONS Among HF patients in sinus rhythm, higher LVEFs were associated with a linear decrease
in mortality up to an LVEF of 45%. However, increases above 45% were not associated with
further reductions in mortality. (J Am Coll Cardiol 2003;42:736–42) © 2003 by the
American College of Cardiology Foundation
The syndrome of heart failure (HF) occurs in patients with
a full range of left ventricular ejection fraction (LVEF).
Although LVEF is an accepted indicator of prognosis in
HF patients, the relationship of LVEF, mortality, and cause
of death across the full spectrum of LVEF is incompletely
understood (1–11). Previous studies examining the prog-
nostic value of LVEF have significant limitations, including
that they were based on small numbers of patients
(4,9,11,12) or limited to high-risk populations (1,5,9,10).
More importantly, these studies failed to demonstrate how
the association of LVEF and mortality changes across the
full spectrum of LVEF because they did not include
substantial numbers of patients with preserved systolic
function (1,3,4,6,7) or examined LVEF as a dichotomous
rather than an ordinal or continuous variable (5–7).
Current American College of Cardiology/American
Heart Association guidelines recommend the routine as-
sessment of LVEF in HF patients to guide therapy, but fall
short of defining a relationship between LVEF and prog-
nosis (13). In addition, little information is available con-
cerning specific causes of death in HF populations, partic-
ularly among patients with preserved systolic function. A
more complete understanding of how the association of
LVEF, mortality, and cause of death varies across the full
LVEF spectrum would improve estimates of prognosis and
may support the use of targeted interventions in specific
populations.
The Digitalis Investigation Group (DIG) trial was a
randomized clinical trial that enrolled a large number of
stable HF patients and included patients with a full range of
LVEF (14). The detailed information available on these
patients provides an ideal opportunity to examine the
association of LVEF, mortality, and cause of death among
stable patients with HF and a full range of LVEF.
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METHODS
The DIG trial. The DIG trial was conducted to examine
the effect of digitalis on mortality and hospitalization in HF
patients (14,15). Patients with stable, clinically confirmed
HF in sinus rhythm (n  7,788) were randomized to
digitalis or placebo at 302 centers in the U.S. and Canada.
Randomization was stratified by both enrolling center and
LVEF: patients with LVEF  45% (n  6,800) were
enrolled in the main arm of the trial, and patients with
LVEF 45% (n 988) were enrolled in a parallel ancillary
arm. Because the eligibility criteria and follow-up were
otherwise identical, we combined data from both arms to
include a full spectrum of LVEF.
LVEF determination. In the DIG trial, LVEF was mea-
sured in all patients before enrollment using either echocar-
diography, equilibrium radionuclide angiography (ERNA),
or contrast ventriculography. The DIG investigators re-
corded a single value of LVEF in each patient and used
LVEF measurements performed up to six months before
enrollment unless the patient had an intervening event. If
more than one technique had been used, angiographic and
radionuclide techniques were deemed equally acceptable,
and either was preferred to echocardiographic measures. For
this analysis, patients were divided into six groups that
demonstrated the association of LVEF and outcomes but
retained enough patients in each group to make meaningful
comparisons: LVEF 15%, 16% to 25%, 26% to 35%, 36%
to 45%, 46% to 55%, and 55%.
Outcomes. We examined all-cause mortality, death due to
arrhythmia, and death due to worsening HF over a median
follow-up of 37 months. Cause of death was assigned by
local investigators blinded to treatment assignment on the
basis of chart review and interview of relatives (14,15).
Statistical analysis. We evaluated the association of LVEF
and patient characteristics using chi-square trend analyses
for categorical variables and Wilcoxon test for trend for
continuous variables (16). We compared crude overall and
cause-specific mortality rates across LVEF groups using
global and test for trend chi-square analyses. Kaplan-Meier
survival curves were plotted for each LVEF group and
compared using log-rank test.
Multivariable analyses were conducted to determine
whether other clinical characteristics confounded the asso-
ciation of LVEF and mortality. Candidate covariates were
identified using a backward stepwise Cox proportional
hazards model with an entry criterion of p  0.1 and a
retention criterion of p  0.01. Independent predictors of
mortality incorporated into multivariable analysis were age,
gender, body mass index (BMI), HF etiology, New York
Heart Association class, diabetes, radiologic evidence of
pulmonary edema on admission or in the past, cardiotho-
racic ratio, blood pressure, creatinine, S3, rales, previous use
of digitalis, angiotensin-converting enzyme inhibitors, di-
uretics, nitroglycerin, and study drug assignment.
We conducted two secondary analyses to confirm the
robustness of LVEF’s association with mortality. First,
LVEF groups were replaced with a single continuous LVEF
measure to assess the linearity of LVEF’s association with
mortality using fractional polynomial modeling (17). Sec-
ond, the Cox proportional hazards multivariable analysis
was repeated restricting the cohort to patients in whom
LVEF was measured by ERNA. Statistical analyses were
performed using SAS 8.02 (SAS Institute Inc., Cary, North
Carolina) and Stata 7.0 (Stata Corporation, College Station,
Texas).
RESULTS
Study sample. The LVEF was measured by ERNA (n 
5,074, 65.2%), left ventricular contrast angiography
(n  428, 5.5%), or two-dimensional echocardiography
(n  2,296, 29.4%). The use of these techniques was
comparable across LVEF groups. Patients with lower
LVEF were younger and a greater proportion were male
compared with patients with higher LVEF. Patients with
low LVEF had lower rates of hypertension and diabetes, as
well as lower systemic blood pressures, BMI, and serum
potassium. In contrast, rates of previous myocardial infarc-
tion (MI), ischemic HF, heart rates, and serum creatinine
were higher among patients in lower LVEF groups (Table
1).
LVEF and crude mortality rates. The overall crude mor-
tality rate was 33.5% with a 28.2% absolute difference
between patients in the lowest and highest LVEF groups
(LVEF  15%: 51.7%; LVEF  55%: 23.5%; p  0.001)
(Fig. 1, Table 2). The association of LVEF and mortality
changed across the full spectrum of LVEF. Among patients
with LVEF 45%, mortality rates increased in a near linear
fashion across successively lower LVEF groups (LVEF 
15%: 51.7%; LVEF 36% to 45%: 25.6%; p  0.001). In
contrast, mortality rates were comparable for patients in
LVEF groups above 45% (LVEF 46% to 55%: 23.3%;
LVEF  55%: 23.5%; p  0.25). Each LVEF group below
45% was associated with shorter survival time (log-rank p
0.001, Fig. 2), but the mortality of patients with LVEF 46%
to 55% was not significantly different than that of patients
with LVEF  55% (log-rank p  0.92). The results were
similar when the analysis was restricted to patients with an
LVEF measured by ERNA (data not shown).
LVEF as an independent predictor of mortality. After
multivariable adjustment, lower LVEF values were inde-
pendently associated with increased mortality among pa-
Abbreviations and Acronyms
BMI  body mass index
DIG  Digitalis Investigation Group
ERNA  equilibrium radionuclide angiography
HF  heart failure
LVEF  left ventricular ejection fraction
MI  myocardial infarction
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tients with LVEF  45%, but the magnitude of the
association was reduced (Table 3). The mortality observed
in LVEF groups above 45% remained comparable.
LVEF and cause of death. Worsening HF and arrhythmia
were the leading specific causes of death (Table 2). Deaths
due to arrhythmias, worsening HF, and other cardiac causes
were more frequent among patients in lower LVEF groups
(p  0.0001 for trend). Deaths due to non-cardiovascular
causes were more frequent among patients with LVEF 
45% (p 0.046 for trend). Worsening and arrhythmias HF
were leading causes of death in all LVEF groups, including
patients with relatively preserved systolic function (Fig. 3).
DISCUSSION
Previous investigators have attempted to characterize the
relationship between LVEF and mortality in HF patients,
with inconsistent results (3,4,6–9,11,12,18–23). Our find-
ings help resolve the conflicting findings of previous studies
and provide several important insights into the association
of LVEF and mortality.
In contrast to previous investigations, we demonstrated
that the association of LVEF and mortality changes sub-
stantially across the full spectrum of LVEF. Studies that
dichotomized LVEF (6,7,23) may have obscured the dy-
namic nature of this association. Those that examined
LVEF as a continuous variable, several did not describe the
association of LVEF and mortality across the full spectrum
of LVEF (1,2). The remaining studies had significant
limitations in that they were small (9,11), limited to patients
with ischemic HF (10), or included few patients with
preserved LVEF (3). Although our analysis does not iden-
tify the precise inflection point above which further in-
creases in LVEF are not associated with lower mortality, it
strongly suggests that the transition occurs in the range of
40% to 50%.
Previous investigators have concluded that the prognostic
utility of LVEF declines once its value falls below 25%
(13,24). In contrast, we found that the crude mortality of
patients with LVEF  15% was 10% higher than that of
patients with an LVEF of 16% to 25%, and within this
Table 1. Baseline Characteristics Stratified by LVEF
Total
(n  7,788)
LVEF
< 15%
(n  567)
LVEF
16% to 25%
(n  2,118)
LVEF
26% to 35%
(n  2,477)
LVEF
36% to 45%
(n  1,638)
LVEF
46% to 55%
(n  593)
LVEF
> 55%
(n  395)
p for
Trend
Demographics
Age (SD) 63.9 (10.9) 61.9 (10.6) 63.2 (11.1) 63.7 (11.0) 64.2 (10.7) 66.0 (10.3) 68.0 (10.2) 0.01
Female (%) 24.7 16.9 19.0 21.8 29.4 33.9 52.2 0.01
Black (%) 14.5 18.2 16.0 13.2 13.4 12.5 16.0 0.01
BMI (SD) 27.3 (5.4) 26.4 (4.9) 26.9 (5.2) 27.1 (5.2) 27.6 (5.3) 28.3 (5.5) 29.2 (7.1) 0.01
Clinical history
Failure on CXR (%) 60.0 66.0 62.9 59.3 56.8 56.2 59.7 0.01
MI (%) 63.0 54.9 62.5 70.2 63.8 57.2 38.0 0.01
Diabetes (%) 28.5 22.8 27.5 30.3 28.8 29.0 28.6 0.04
Hypertension (%) 47.2 40.4 43.3 44.5 51.0 55.5 66.1 0.01
Ischemic HF (%) 68.8 61.7 67.3 74.9 71.6 64.6 44.1 0.01
Signs/symptoms on enrollment
Rales (%) 16.7 23.5 19.7 15.3 13.2 16.2 14.9 0.01
S3 (%) 23.7 42.5 30.5 23.5 16.6 11.1 9.4 0.01
Angina (%) 27.2 23.5 24.6 28.1 28.8 30.2 29.1 0.01
Heart rate: mean (SD) 78.4 (12.2) 82.2 (13.2) 80.3 (12.9) 77.8 (12.3) 76.9 (12.2) 75.8 (12.3) 75.8 (11.5) 0.01
BP (mm Hg)
Systolic (SD) 127.3 (20.5) 116.7 (17.5) 123.1 (19.6) 126.6 (19.6) 131.3 (19.9) 135.5 (20.4) 140.6 (22.2) 0.01
Diastolic (SD) 75.1 (11.3) 74.0 (11.3) 74.4 (11.4) 74.5 (11.1) 76.4 (11.1) 76.9 (11.0) 76.7 (11.9) 0.01
HF duration (months) 29.7 30.7 30.6 30.1 29.5 27.0 26.2 0.01
NYHA class: III/IV (%) 31.3 52.2 38.5 29.2 23.6 19.6 25.8 0.01
Laboratory or X-ray data
Failure on CXR (%) 14.2 22.4 18.0 13.4 10.3 9.8 10.9 0.01
CT ratio (%) 53.1 56.4 54.5 52.6 52.0 51.4 52.1 0.01
Serum creatinine (mg/dl) 1.28 1.31 1.31 1.28 1.26 1.26 1.25 0.01
LVEF technique
ERNA 65.2 63.0 64.3 64.2 66.1 70.2 67.6% 0.05
Echocardiography 29.4 32.3 31.1 29.5 27.7 25.6 27.6% 0.07
Contrast ventriculography 5.5 4.8 4.7 6.3 6.3 4.2 4.8% 0.03
Medication on admission
Digoxin (%) 43.2 52.6 47.0 44.0 38.6 33.9 37.2 0.01
Diuretics (%) 81.5 90.7 86.3 79.5 76.1 79.1 82.3 0.01
ACE inhibitor (%) 93.4 95.1 96.1 94.4 92.1 87.0 85.1 0.01
Nitrates (%) 42.2 42.9 42.3 44.0 41.0 39.6 39.0 0.07
ACE  angiotensin-converting enzyme; BMI  body mass index; BP  blood pressure; CT  cardiac–thoracic; CXR  chest X-ray; ERNA  equilibrium radionuclide
angiography; HF  heart failure; LVEF  left ventricular ejection fraction; MI  myocardial infarction; NYHA  New York Heart Association; SD  standard deviation.
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interval higher measures of LVEF were associated with a
linear decline in mortality (Fig. 1). After multivariable
adjustment, the difference between these groups was not
statistically significant. However, the adjusted hazard ratio
of patients with LVEF  15% was 23% higher than that of
patients with LVEF 16% to 25%, and the magnitude of this
difference was similar to that observed between other LVEF
groups. Accordingly, our findings suggest that the graded
and continuous relationship between LVEF and mortality is
present even among patients with severely depressed systolic
function.
In this large group of patients with established HF (mean
previous duration of HF 2.5 years), the mortality rates
associated with individual LVEF groups were stable over
time. We found no evidence of an increased early hazard
among patients with severe LV dysfunction, nor was there
an indication of increased late mortality in any LVEF
group. Our findings would suggest that on average, LVEF
is associated with a constant, fixed mortality risk. As such,
survival for several years with a lower LVEF may not
necessarily indicate a better future prognosis.
We found the relative risk associated with LVEF to be
modest in comparison with the MI experience, as shown by
the less than threefold difference in mortality rates between
patients in the lowest and highest LVEF groups. In MI
populations, LVEF is associated with a more than 10-fold
relative difference in mortality rates (25). The difference in
the prognostic significance of LVEF in these cohorts is due
to the mortality observed in HF patients with preserved
LVEF. Thus, our findings emphasize the substantial mor-
tality risk associated with the syndrome of HF irrespective
of LVEF.
Finally, the strength of the association of LVEF and
mortality was reduced by multivariable adjustment, indicat-
ing that a substantial portion of the increased risk of death
observed in patients with systolic dysfunction could be
Figure 1. Linear trend for left ventricular ejection fraction (LVEF) as a continuous variable and unadjusted all-cause mortality. Each point represents the
mortality rate associated with each LVEF point.
Table 2. Crude Mortality and Cause of Death
Total
(n  7,788)
LVEF
< 15%
(n  567)
LVEF
16% to 25%
(n  2,118)
LVEF
26% to 35%
(n  2,477)
LVEF
36% to 45%
(n  1,638)
LVEF
46% to 55%
(n  593)
LVEF
> 55%
(n  395)
p for
Trend# % # % # % # % # % # % # %
Overall mortality 2,606 33.5 293 51.7 884 41.7 778 31.4 420 25.6 138 23.3 93 23.5 0.01
Cause of death
Cardiovascular 2,052 26.3 265 46.7 730 34.5 597 24.1 298 18.2 100 16.9 62 15.7 0.01
Arrhythmic 583 7.5 79 13.9 217 10.2 155 6.3 96 5.9 25 4.2 11 2.8 0.01
Worsening HF 907 11.6 148 26.1 333 15.7 268 10.8 94 5.7 34 5.7 30 7.6 0.01
Other cardiac 451 5.8 35 6.2 150 7.1 143 5.8 77 4.7 33 5.6 13 3.3 0.00
Stroke 57 0.7 1 0.2 17 0.8 17 0.7 15 0.9 3 0.5 4 1.0 0.36
Embolism 18 0.2 0 0.0 7 0.3 3 0.1 6 0.4 1 0.2 1 0.3 0.67
Other vascular 36 0.5 2 0.4 6 0.3 11 0.4 10 0.6 4 0.7 3 0.8 0.07
Noncardiovascular 410 5.3 20 3.5 107 5.1 129 5.2 99 6.0 29 4.9 26 6.6 0.05
Unknown 144 1.8 8 1.4 47 2.2 52 2.1 23 1.4 9 1.5 5 1.3 0.15
HF  heart failure; LVEF  left ventricular ejection fraction.
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explained by other differences between groups. Although
LVEF is a strong independent predictor of mortality in HF
patients, the prognostic value of LVEF should be inter-
preted in the context of other established risk factors.
Our study also adds insight into the prognosis of patients
with HF and preserved systolic function that may account
for up to half of all hospital admissions for HF (12,26–29).
Although these patients have lower mortality compared
with patients with systolic dysfunction, they are at increased
risk of death compared with patients without HF
(12,22,30). The annual mortality reported in previous stud-
ies ranges from 1.3% to 17.5% (12,27–35), but the variation
in these estimates appears mainly due to differences in
patient characteristics. We found that patients with rela-
Figure 2. Kaplan-Meier survival curves stratified by left ventricular ejection fraction (LVEF) group.
Table 3. LVEF and Mortality: Multivariable Analysis
LVEF < 15% LVEF 16% to 25% LVEF 26% to 35% LVEF 36% to 45%* LVEF 46% to 55% LVEF > 55%
Unadjusted 2.66 (2.26, 3.14) 1.85 (1.66, 2.07) 1.28 (1.14, 1.43) 1.00 0.88 (0.73, 1.05) 0.88 (0.71, 1.08)
Adjusted: [1] 2.66 (2.25, 3.14) 1.82 (1.63, 2.04) 1.26 (1.12, 1.41) 1.00 0.85 (0.71, 1.02) 0.82 (0.66, 1.02)
Adjusted: [2] 2.03 (1.71, 2.41) 1.56 (1.39, 1.75) 1.15 (1.02, 1.29) 1.00 0.87 (0.73, 1.05) 0.83 (0.67, 1.04)
Adjusted: [3] 1.84 (1.54, 2.18) 1.47 (1.30, 1.65) 1.13 (1.01, 1.26) 1.00 0.91 (0.76, 1.09) 0.89 (0.71, 1.10)
Adjusted: [4] 1.77 (1.49, 2.11) 1.44 (1.28, 1.61) 1.10 (0.98, 1.28) 1.00 0.92 (0.97, 1.10) 0.88 (0.71, 1.09)
*Reference group: left ventricular ejection fraction (LVEF) 36% to 45%. [1] Demographics  History. [2] Demographics  History  Admission. [3] Demographics  History
 Admission  Laboratory. [4] Demographics  History  Admission  Laboratory  Previous medications  Study drug assignment.
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tively preserved systolic function had an average annual
mortality of 5.8%, which is comparable to the 8.7% previ-
ously observed in the Framingham Study (27).
The causes of death in HF populations with preserved
systolic function are also incompletely defined. Previous
investigations have found these patients frequently die of
cardiovascular causes (12,28–31), but these studies were
small and employed variable classification schemes. Not
unexpectedly, we found the incidence of specific causes of
death varies with LVEF. Patients with LVEF  15% were
four times more likely to die of either arrhythmia or
worsening HF than patients with LVEF  45%. Neverthe-
less, deaths due to arrhythmias and worsening HF were
common among patients with LVEF  45%. In addition,
the high absolute rate of arrhythmic mortality suggests the
need to develop strategies aimed at reducing the risk of
lethal arrhythmias, including risk stratification, use of beta-
blockers, and possibly consideration of implantable cardiac
defibrillators in HF patients with higher LVEF than those
previously enrolled in randomized trials. Although deter-
mining a specific cause of death in HF patients is difficult
and may be prone to error (36), our results should serve as
a basis for the design and implementation of strategies
aimed at decreasing mortality in this understudied popula-
tion.
Several aspects of our study merit further consideration.
The DIG trial did not standardize the technique or inter-
pretation of LVEF measurement. Because measurement
techniques were similar across the LVEF groups, any
misclassification of LVEF would presumably have been
evenly distributed and thus produced no net bias. Further-
more, our results were similar when we restricted our
analysis to patients who had an ERNA-assessed LVEF.
The DIG trial protocol did not specify measurement
of functional capacity, such as peak oxygen capacity. In
addition, since the completion of the DIG trial, increased
use of beta-blockers and spironolactone in patients with
LV systolic dysfunction might have narrowed the difference
in mortality between HF patients with LVEF above and
below 45%. Finally, patients in the DIG trial were younger
and had fewer comorbidities than HF patients in observa-
tional cohorts (37,38). It is unclear if the association of
LVEF and mortality would be similar in patients with
additional comorbidities. Nevertheless, this is the largest
study of stable HF patients to include a full spectrum of
LVEF, and our results should serve as a viable estimate of
risk conferred by LVEF until additional studies are com-
pleted.
In summary, our study demonstrates that the association
of LVEF and mortality changes substantially across the full
spectrum of LVEF. This information clarifies the role of
LVEF in HF patients and will help clinicians provide better
estimates of prognosis. In addition, understanding that
arrhythmias and worsening HF contribute to substantial
mortality observed in patients with HF with preserved
LVEF may help target future interventions in this popula-
tion.
Figure 3. Proportion of death attributed to specific causes of death across left ventricular ejection fraction groups. HF  heart failure.
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